Ron Yu
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Research top 10%
Papers in
- Oncology 17
- HER2/EGFR in Cancer Research 9
- Cancer Treatment and Pharmacology 7
-
- Angiogenesis and VEGF in Cancer 4
- Cell death mechanisms and regulation 2
- Co-authors
- Tingjun Hou (1 shared paper)Antonio González-Martı́n (5 shared papers)Hans Wildiers (5 shared papers)Melanie C. Smitt (3 shared papers)Ian E. Krop (4 shared papers)Patricia LoRusso (3 shared papers)Abraham C.F. Leung (3 shared papers)Sung‐Bae Kim (3 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)Contemporary Clinical Trials (3 papers)Annals of Oncology (2 papers)Blood (1 paper)British Journal of Cancer (1 paper)
- Partner nations
- United StatesSouth KoreaSpain
In The Last Decade
Ron Yu
30 papers receiving 1.7k citations
Ron Yu's Hit Papers
Peers
Comparison fields: 5 of 99
- Oncology 949
- Cancer Research 264
- Radiology, Nuclear Medicine and Imaging 391
- Genetics 136
- Virology 54
Countries citing papers authored by Ron Yu
This map shows the geographic impact of Ron Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Yu more than expected).
Fields of papers citing papers by Ron Yu
This network shows the impact of papers produced by Ron Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Yu. The network helps show where Ron Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Ron Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 512 |
| 2 | 2007 | 241 | |
| 3 | 2010 | 175 | |
| 4 | 2005 | 117 | |
| 5 | 2004 | 84 | |
| 6 | 2014 | 75 | |
| 7 | 2014 | 72 | |
| 8 | 2006 | 70 | |
| 9 | 2016 | 68 | |
| 10 | 2005 | 65 | |
| 11 | 2014 | 61 | |
| 12 | 2005 | 51 | |
| 13 | 2016 | 26 | |
| 14 | 2013 | 23 | |
| 15 | 2012 | 13 | |
| 16 | 2013 | 13 | |
| 17 | 2006 | 12 | |
| 18 | 2022 | 11 | |
| 19 | 2016 | 11 | |
| 20 | 2013 | 9 |
About Ron Yu
Ron Yu is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 32 papers that have together received 1.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers), Gastric Cancer Management and Outcomes (4 papers), Angiogenesis and VEGF in Cancer (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Statistical Methods in Clinical Trials (3 papers), Advanced Breast Cancer Therapies (3 papers) and Cell death mechanisms and regulation (2 papers). The work is most often cited by research in Oncology (949 citations), Cancer Research (264 citations), Radiology, Nuclear Medicine and Imaging (391 citations), Genetics (136 citations) and Virology (54 citations). Ron Yu has collaborated with scholars based in United States, South Korea and Spain. Frequent co-authors include Tingjun Hou, Antonio González-Martı́n, Hans Wildiers, Melanie C. Smitt, Ian E. Krop, Patricia LoRusso, Abraham C.F. Leung, Sung‐Bae Kim, Jean-Marc Ferrero and Branimir I. Šikić. Their work appears in journals such as Journal of Clinical Oncology, Contemporary Clinical Trials, Annals of Oncology, Blood and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.